EICHORCondition: KRAS P.G12C · Non Small Cell Lung Cancer · Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study aims to provide a comprehensive understanding of sotorasib's mechanisms of action and resistance in NSCLC patients.
This description comes directly from the study's public registry record.
Lynda MATI · +33 1 42 11 42 11 · Lynda.mati@gustaveroussy.fr
Always discuss trial participation with your own doctor first.
| Centre Léon Bérard | Lyon, France | Recruiting |
| AP-HM Hôpital Nord | Marseille, France | Recruiting |
| Hôpital Paris Saint Joseph | Paris, France | Recruiting |
| AP-HP Hôpital Tenon | Paris, France | Not Yet Recruiting |
| Gustave Roussy | Villejuif, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05631249